Literature DB >> 25734736

Irritable bowel syndrome: a clinical review.

William D Chey1, Jacob Kurlander1, Shanti Eswaran1.   

Abstract

IMPORTANCE: Irritable bowel syndrome (IBS) affects 7% to 21% of the general population. It is a chronic condition that can substantially reduce quality of life and work productivity.
OBJECTIVES: To summarize the existing evidence on epidemiology, pathophysiology, and diagnosis of IBS and to provide practical treatment recommendations for generalists and specialists according to the best available evidence. EVIDENCE REVIEW: A search of Ovid (MEDLINE) and Cochrane Database of Systematic Reviews was performed for literature from 2000 to December 2014 for the terms pathophysiology, etiology, pathogenesis, diagnosis, irritable bowel syndrome, and IBS. The range was expanded from 1946 to December 2014 for IBS, irritable bowel syndrome, diet, treatment, and therapy.
FINDINGS: The database search yielded 1303 articles, of which 139 were selected for inclusion. IBS is not a single disease but rather a symptom cluster resulting from diverse pathologies. Factors important to the development of IBS include alterations in the gut microbiome, intestinal permeability, gut immune function, motility, visceral sensation, brain-gut interactions, and psychosocial status. The diagnosis of IBS relies on symptom-based criteria, exclusion of concerning features (symptom onset after age 50 years, unexplained weight loss, family history of selected organic gastrointestinal diseases, evidence of gastrointestinal blood loss, and unexplained iron-deficiency anemia), and the performance of selected tests (complete blood cell count, C-reactive protein or fecal calprotectin, serologic testing for celiac disease, and age-appropriate colorectal cancer screening) to exclude organic diseases that can mimic IBS. Determining the predominant symptom (IBS with diarrhea, IBS with constipation, or mixed IBS) plays an important role in selection of diagnostic tests and treatments. Various dietary, lifestyle, medical, and behavioral interventions have proven effective in randomized clinical trials. CONCLUSIONS AND RELEVANCE: The diagnosis of IBS relies on the identification of characteristic symptoms and the exclusion of other organic diseases. Management of patients with IBS is optimized by an individualized, holistic approach that embraces dietary, lifestyle, medical, and behavioral interventions.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25734736     DOI: 10.1001/jama.2015.0954

Source DB:  PubMed          Journal:  JAMA        ISSN: 0098-7484            Impact factor:   56.272


  286 in total

1.  Rebuttal from Terence K. Smith and Michael D. Gershon.

Authors:  Terence K Smith; Michael D Gershon
Journal:  J Physiol       Date:  2015-08-01       Impact factor: 5.182

Review 2.  Stress and glucocorticoid receptor transcriptional programming in time and space: Implications for the brain-gut axis.

Authors:  J W Wiley; G A Higgins; B D Athey
Journal:  Neurogastroenterol Motil       Date:  2016-01       Impact factor: 3.598

3.  Rare Variants of the Serotonin Transporter Are Associated With Psychiatric Comorbidity in Irritable Bowel Syndrome.

Authors:  Ruth Kohen; Julia H Tracy; Eric Haugen; Kevin C Cain; Monica E Jarrett; Margaret M Heitkemper
Journal:  Biol Res Nurs       Date:  2016-02-24       Impact factor: 2.522

Review 4.  Prevalence, Risk Factors, and Outcomes of Irritable Bowel Syndrome After Infectious Enteritis: A Systematic Review and Meta-analysis.

Authors:  Fabiane Klem; Akhilesh Wadhwa; Larry J Prokop; Wendy J Sundt; Gianrico Farrugia; Michael Camilleri; Siddharth Singh; Madhusudan Grover
Journal:  Gastroenterology       Date:  2017-01-06       Impact factor: 22.682

5.  Understanding and Managing IBS and CIC in the Primary Care Setting.

Authors:  Brooks D Cash
Journal:  Gastroenterol Hepatol (N Y)       Date:  2018-05

6.  SYMPOSIUM REPORT: An Evidence-Based Approach to IBS and CIC: Applying New Advances to Daily Practice: A Review of an Adjunct Clinical Symposium of the American College of Gastroenterology Meeting October 16, 2016 • Las Vegas, Nevada.

Authors:  William D Chey
Journal:  Gastroenterol Hepatol (N Y)       Date:  2017-02

Review 7.  Probiotics, fibre and herbal medicinal products for functional and inflammatory bowel disorders.

Authors:  Diego Currò; Gianluca Ianiro; Silvia Pecere; Stefano Bibbò; Giovanni Cammarota
Journal:  Br J Pharmacol       Date:  2016-10-25       Impact factor: 8.739

8.  5-HT3 receptor signaling in serotonin transporter-knockout rats: a female sex-specific animal model of visceral hypersensitivity.

Authors:  Nadine El-Ayache; James J Galligan
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2018-10-25       Impact factor: 4.052

9.  Chronic linaclotide treatment reduces colitis-induced neuroplasticity and reverses persistent bladder dysfunction.

Authors:  Luke Grundy; Andrea M Harrington; Joel Castro; Sonia Garcia-Caraballo; Annemie Deiteren; Jessica Maddern; Grigori Y Rychkov; Pei Ge; Stefanie Peters; Robert Feil; Paul Miller; Andre Ghetti; Gerhard Hannig; Caroline B Kurtz; Inmaculada Silos-Santiago; Stuart M Brierley
Journal:  JCI Insight       Date:  2018-10-04

10.  Patients with primary restless legs syndrome have higher prevalence of autonomic dysfunction and irritable bowel syndrome.

Authors:  Bilgehan Atılgan Acar; Mustafa Atahan Gürkan Acar; Türkan Acar; Ceyhun Varım; Aybala Neslihan Alagöz; Enis Bekir Demiryürek; Belma Doğan Güngen; Yeşim Güzey Aras
Journal:  Singapore Med J       Date:  2018-01-26       Impact factor: 1.858

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.